title: Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
abstract: BACKGROUND
  Reboxetine is a novel selective noradrenaline reuptake inhibitor. The antidepressive properties of the substance are established.
  
  
  METHODS
  The influence of reboxetine on the sleep-EEG of eight patients with depression HAMD (mean +/- SD) 19.7 +/- 1.5 (5 women, 3 men; age range 31 to 75 years) was investigated. Sleep EEG was examined twice. The first examination was performed before starting active medication. The second examination was subsequently performed when patients received 8 to 10 mg reboxetine per day.
  
  
  RESULTS
  Conventional sleep-EEG analysis showed a significant increase in intermittent wakefulness and sleep stage 2 and a decrease in sleep efficiency and REM time. Under reboxetine no significant changes were observed in sleep-EEG spectral analysis.
  
  
  CONCLUSIONS
  Our results indicate, that reboxetine induces sleep-EEG changes similar to those after selective serotonin reuptake inhibitors (SSRI's) by increasing intermittent wakefulness and decreasing REM time.
authors.affiliation: Max Planck Institute of Psychiatry, Munich, Germany.
authors.forename: H E
authors.initials: HE
authors.lastname: Kuenzel
authors.forename: H
authors.initials: H
authors.lastname: Murck
authors.forename: K
authors.initials: K
authors.lastname: Held
authors.forename: M
authors.initials: M
authors.lastname: Ziegenbein
authors.forename: A
authors.initials: A
authors.lastname: Steiger
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use*; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced*; D012894:Sleep Stages / Q000187:drug effects*; D014851:Wakefulness / Q000187:drug effects
chemical_list: D018759:Adrenergic Uptake Inhibitors; D005473:Fluoxetine; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors